All lineages of haematopoietic cells, including those of the immune system, arise from a rare population of self-renewing HSCs residing in the bone marrow (BM) of adult mammals 1 . Blood production by HSCs is regulated by the concerted action of cell-intrinsic transcription factors such as PU.1 and GATA-1, and cell-extrinsic determinants produced by the stromal and haematopoietic components of the BM niche, which together regulate HSC self-renewal and specify lineage commitment 2, 3 . Although normally maintained in a largely quiescent or dormant state, most HSCs can be rapidly activated to proliferate and differentiate in response to acute needs such as regenerative challenges including myeloablation and transplantation, and physiological insults that induce an inflammatory state [4] [5] [6] . Inflammation is a critical physiological process that mediates host defence against invading pathogens, injury and other insults, and is characterized by rapid mobilization and overproduction of specialized immune cells, particularly myeloid cells 7 . Inflammation is communicated to the haematopoietic system, and HSCs in particular, either by direct sensing through Toll-like receptors (TLRs), or indirectly through a series of pro-inflammatory cytokines [8] [9] [10] . In particular, interferons (IFNs), both type-I (IFN-α/β) and type-II (IFN-γ), and tumour necrosis factor alpha (TNFα) directly impact HSC fate during an inflammatory response [11] [12] [13] [14] and drive HSC specification during embryonic development 15, 16 . Pro-inflammatory cytokines are therefore exciting new regulators of HSC function 17 , with much remaining to be understood regarding how inflammatory insults tailor blood production under homeostatic and disease conditions.
Interleukin-1 (IL-1) was the first interleukin identified and is the founding member of a group of 11 cytokines (the IL-1 family), with a central role in responses to infections or sterile insults 18, 19 . IL-1 consists of two related genes (Il1a and Il1b) with distinct regulation but similar biological activities 18 , which bind a broadly expressed surface receptor (IL-1R) and trigger downstream transcriptional responses through the adaptor protein MyD88 and a broad range of signalling pathways including NF-κB, p38 MAPK, JNK and AP-1 (ref. 20) . IL-1 is a key 'emergency' signal that rapidly activates host defence and repair in many tissues, including the blood system, but also drives tissue dysfunction in the context of chronic inflammation and autoimmune diseases 7, 19 . Acute IL-1 signalling is 1 
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associated with increased myeloid cell production both in culture and in vivo in response to infection, irradiation or myeloablative chemotherapy [21] [22] [23] [24] . Many of the inflammatory disease conditions associated with chronic IL-1 production such as rheumatoid arthritis, obesity and type-2 diabetes also feature severe haematological complications, including overproduction of tissue-damaging myeloid cells, loss of naive lymphoid cell production and chronic anaemia [25] [26] [27] . However, the mechanism by which IL-1 contributes to deregulated blood output in these conditions, and the functional consequences of both acute and chronic IL-1 exposure on HSC fate, is largely unknown.
RESULTS

IL-1 accelerates HSC differentiation
To investigate IL-1 effects, we isolated HSCs (Lin − c-Kit Supplementary Fig. 1a ) from wild-type mice and monitored their expansion in liquid culture with or without (±) IL-1α or IL-1β (25 ng ml −1 ). Notably, HSCs cultured with IL-1 differentiated and expanded significantly faster than untreated HSCs over an 8-day period (Fig. 1a) , which seemed to result from faster division rates as measured by carboxyfluorescein succinimidyl ester (CFSE) dilution assay after 60 h (Fig. 1b) . To confirm accelerated cell division in HSC cultures, we used an automated single-cell tracking approach to continuously monitor cell division over a 6-day period (Fig. 1c) 
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. Remarkably, although the timing of the exit from quiescence first division seemed relatively unaffected in IL-1-treated HSCs, the kinetics of the subsequent differentiation divisions were significantly compressed (Fig. 1d,e 29, 30 , which all express IL-1R at similar levels to HSCs ( Supplementary Fig. 1a-e) . These results indicate that IL-1 specifically targets HSCs and accelerates their division kinetics.
To directly address the effects of IL-1 on HSC differentiation, we performed colony formation assays in methylcellulose ± IL-1β (Fig. 1f) . Strikingly, IL-1-treated HSCs produced almost exclusively myeloid-committed granulocyte/macrophage (GM)-type colonies containing abundant macrophages, in contrast to untreated HSCs, which had a higher proportion of immature multilineage granulocyte/macrophage/megakaryocyte/erythrocyte (GMMkE)-type colonies containing mostly immature myeloblasts and mast cells (Fig. 1g,h ). We also re-plated the progeny of these cultures once in methylcellulose without IL-1β, and observed near exhaustion of colony-forming ability in cells from IL-1-treated HSC cultures (Fig. 1i) . Moreover, HSCs grown in liquid culture with IL-1β rapidly lost expression of the immaturity markers c-Kit and Sca-1, and gained expression of the myeloid differentiation markers Mac-1 and FcγR, resulting in greatly increased absolute numbers of c-Kit+ progenitors and mature myeloid cells in IL-1-treated HSC cultures (Fig. 1j,k and Supplementary Fig. 1f ). This pro-myeloid differentiation effect was diminished in MPPs and completely absent in GMPs ( Supplementary  Fig. 2a-e) . Collectively, these results demonstrate that IL-1 accelerates the production of mature myeloid cells by HSCs.
Precocious activation of a PU.1 molecular circuit
To understand the effects of IL-1 at the molecular level, we used quantitative PCR with reverse transcription (qRT-PCR) and a custommade Fluidigm PCR array to analyse gene expression in HSCs cultured ± IL-1β for 12 or 24 h (Fig. 2a and Supplementary Fig. 3a) . Remarkably, we observed a strong induction of the transcription factor PU.1 (Spi1) and its target genes Csf2ra (GM-CSFR) and Csf1r (M-CSFR) in IL-1-treated HSCs ( Fig. 2b and Supplementary Fig. 3b ). In contrast, lymphoid and megakaryocyte/erythrocyte (MkE) lineage genes were largely unaffected, suggesting that IL-1 functions by activating, rather than suppressing, lineage-specific gene programs in HSCs 31 . Consistent with the effects of IL-1 on cell division, we also observed activation of the cell cycle machinery and decreased expression of the quiescence-enforcing cyclin D1 (Ccnd1) and p57 (Cdkn1c) genes, alongside induction of p21 (Cdkn1a), another PU.1 target (Fig. 2b) . We confirmed rapid upregulation of M-CSFR and two other PU.1-dependent myeloid surface markers, Mac-1 and CD18, in IL-1-treated HSCs (Fig. 2c) , and found limited or absent activation of PU.1 and its target genes in IL-1-treated MPPs and GMPs ( Supplementary Fig. 3b ). Moreover, using HSCs isolated from PU.1-eYFP reporter mice, we confirmed fast upregulation of PU.1 activity on IL-1 exposure, with uniformly high PU.1 levels in IL-1-treated PU.1-eYFP HSCs before their first division in single-cell tracking experiments (Fig. 2d,e and Supplementary Fig. 3c ). We also uncovered a small subpopulation of PU.1 hi HSCs in untreated cultures whose progeny showed division kinetics similar to IL-1-treated HSCs ( Supplementary Fig. 3d ). In particular, both had a delayed first division when compared with untreated PU.1 lo HSCs, consistent with the decreased BrdU incorporation observed after 24 h in IL-1-treated HSCs (Supplementary Fig. 3e ). The subsequent divisions of untreated PU.1 hi HSCs were also accelerated, thus directly linking elevated PU.1 activity with the overall effect of IL-1 in accelerating division kinetics. This is in contrast to the recently reported function of steady-state PU.1 levels in limiting HSC cell cycle re-entry 32 and is likely to reflect differences in gene dosage. In fact, high PU.1 levels similarly delayed HSC first division while simultaneously priming their progeny to undergo accelerated proliferation through induction of myeloid lineage determinants and cell cycle activators including Cdk4, Myc, Ccnb and Ccne1 (Fig. 2b) (Fig. 2g) . These results establish that IL-1 acts instructively and 'primes' HSCs to undergo accelerated myeloid differentiation through precocious activation of a PU.1-dependent molecular circuit.
Mechanism of PU.1 activation
To gain insight into the mechanism of PU.1 activation by IL-1, we first addressed its dependency on IL-1R signalling. As expected, Il1r1 −/− HSCs did not show accelerated myeloid differentiation in the presence of IL-1β (Fig. 3a) , and IL-1-treated Il1r1 −/− ::PU.1-eYFP HSCs failed to upregulate PU.1 (Fig. 3b) . We then exposed PU.1-eYFP HSCs cultured for 12 h ± IL-1β (25 pg ml −1 , a lower dose titrated for sensitivity), to inhibitors of various signalling pathways acting downstream of IL-1R (Fig. 3c,d and Supplementary Fig. 3f,g ) 20 .
Interestingly, whereas blockade of p38, MEK and PKC partially decreased IL-1-induced PU.1 levels, inactivation of IKK almost entirely abolished PU.1 activity, consistent with the ability of its downstream target, NF-κB, to bind the PU.1 promoter 35 . On the other hand, PI(3)K and mTOR inhibition had no effect, and blockade of Src kinase, which drives PU.1 activation downstream of M-CSFR 36 , only partially inhibited IL-1 effects. As M-CSFR expression was increased in IL-1-treated HSCs, we also tested whether IL-1 could directly activate an M-CSF autocrine loop to induce PU.1. However, treatment with an anti-M-CSFR blocking antibody did not attenuate IL-1-mediated PU.1 activation in PU.1-eYFP HSCs, despite preventing M-CSF-mediated macrophage differentiation in BM cultures ( Fig. 3e and Supplementary Fig. 3h) . Furthermore, the effect of IL-1 required constant IL-1R signalling and was lost if IL-1 was washed out * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001. P values in b-e were determined by Mann-Whitney U-test, in f by one-way ANOVA with Dunnett's test, and in g by paired Student's t-test. Exact P values, number of replicates used to derive statistical data (n) and statistical tests used are shown in Supplementary  Table 2 .
after 24 h (Fig. 3f) , further arguing against a role for IL-1-induced secondary factors. These results demonstrate that direct and sustained IL-1 signalling, mediated largely through NF-κB pathway activation downstream of IL-1R, is required for PU.1 induction.
Haematopoietic remodelling following IL-1 exposure
To investigate the effects of IL-1 on haematopoiesis in vivo, we injected mice intraperitoneally with 0.5 µg IL-1β for 1 day (acute treatment) up to 20 consecutive days (chronic exposure; Fig. 4a ). As expected, IL-1-treated mice exhibited a rapid and sustained increase in circulating myeloid cells, with concomitant decreases in lymphoid cells and erythrocytes (Fig. 4b ,c and Supplementary Fig. 4a ). In the BM, 1 day acute IL-1 treatment did not significantly alter the overall cellularity or lineage distribution of mature cell populations, save for a small but significant increase in Mac-1 + Gr-1 int pre-granulocytes/monocytes (preGrs; Supplementary Fig. 4b-d) . However, acute IL-1 treatment already resulted in a rapid MPP expansion and substantial erosion of common lymphoid progenitors (CLPs: Supplementary Fig. 4c,d ), suggesting quick myeloid priming on IL-1 exposure. These changes were maintained and associated with a clear rebalancing of lineage output following 20 days of chronic IL-1 exposure, with significant expansion of Mac-1 + Gr-1 + granulocytes (Grs) and corresponding loss of B220 + CD19 + B cells (Fig. 4d ). This was associated with a specific amplification of GMPs and myeloidbiased MPP2 and MPP3 subsets (Fig. 4e) , suggesting direct activation of a myeloid differentiation axis at the level of HSCs 28 . Consistently, we observed a rapid and sustained increase in the metabolically activated MPP1 (Lin − c-Kit is produced by dormant long-term HSCs (HSC LT ; Lin − c-Kit
, and solely accounted for the overall expansion of phenotypic HSCs observed following 20 days of chronic IL-1 exposure ( Fig. 4g and Supplementary Fig. 4e ). Importantly, HSC activation and BM remodelling was not observed in IL-1-treated Il1r1 −/− mice, confirming its dependency on IL-1R signalling ( Supplementary Fig. 4e ). Moreover, using a sensitive in vivo CFSE dilution assay 37 and 7 consecutive days of IL-1β treatment, we demonstrated that fewer IL-1-treated HSC LT remain in an undivided state compared with untreated HSC LT (Fig. 4h,i and Supplementary  Fig. 5a,b) . This confirms in vivo that IL-1 exposure directly increases HSC division rates, which is likely to fuel the MPP overproduction observed even after acute treatment. In addition, we showed persistent PU.1 activation in a substantial fraction of HSCs from PU.1-eYFP mice on both acute and chronic IL-1 treatment (Fig. 4j) . We also found decreased Cebpa levels and increased Runx1 expression in HSCs exposed to IL-1 for 20 days (Fig. 4k) , which is strikingly similar to the molecular changes observed in regenerating HSCs that overproduce myeloid-biased MPP2/3 as they re-build the myeloid lineage 30 . PU.1 was also activated in MPP4 from IL-1-treated PU.1-eYFP mice ( Supplementary Fig. 5c ), which is likely to reflect the myeloid lineage reprogramming of this lymphoid-primed MPP subset on IL-1 exposure. This is consistent with the observed loss of lymphoid output and previously reported inhibition of lymphopoiesis by IL-1 (ref. 38) . Collectively, these results indicate that in vivo IL-1 exposure triggers a rapid PU.1-mediated myeloid differentiation program in HSCs, which amplifies myeloid cell production at the expense of the other blood lineages. Acute IL-1 stimulation contributes to myeloid recovery To investigate the importance of IL-1 for blood regeneration, we focused on 5-fluorouracil (5-FU)-mediated myeloablation, as we found that both IL-1α and IL-1β levels were significantly increased in BM plasma, but not in blood serum, whereas no other proinflammatory cytokines were induced following one injection of 150 mg kg −1 5-FU ( Fig. 5a and Supplementary Fig. 6a ). To identify the cellular source(s) of IL-1, we analysed Il1a and Il1b expression by qRT-PCR in mature BM myeloid and lymphoid cells, as well as in BM stromal populations 39 , specifically osteoblastic lineage cells (OBCs: Fig. 6b ). At steady state, Il1a was expressed largely by BM CD4 + T cells, and Il1b by Grs (Fig. 5b) . However, on 5-FU treatment, Il1a was strongly induced in myeloid cells and ECs, but no increase in Il1b expression was detected, suggesting that it might be released by dying Grs on inflammasome activation 40 . Strikingly, myeloid recovery was significantly and specifically delayed in 5-FU-injected Il1r1 −/− mice (Fig. 5c) , emphasizing the importance of IL-1R signalling for myeloid recovery following BM injury. However, HSCs isolated from Il1r1 +/+ and Il1r1 −/− mice 10 days post-5-FU treatment, and at the peak of IL-1 production, showed equivalent engraftment and long-term multilineage reconstitution on transplantation (Fig. 5d-g ). This indicates that acute exposure to IL-1 and transient activation of pro-myeloid differentiation pathways required for optimal blood recovery does not affect HSC self-renewal activity. In addition, Il1r1 −/− mice had unaffected blood production as previously described 41 , and normal stem and progenitor BM compartments, aside from a specific decrease in myeloid-biased MPP3 that may represent impaired basal myeloid lineage priming in the absence of tonic IL-1 signalling ( Supplementary Fig. 6c,d) . Together, these results demonstrate that although IL-1 signalling is dispensable in HSCs at steady state, it becomes important in physiological 'emergency' conditions when acute IL-1 production rapidly activates HSC myeloid differentiation to enhance blood regeneration. They also identify ECs as one of the key producers of IL-1 following haematopoietic damage, consistent with a local delivery of IL-1 to quiescent HSCs lodged in their perivascular BM niches 42 .
Chronic IL-1 exposure impairs HSC function
To better understand the consequence of chronic IL-1 exposure, we used HSCs isolated from mice injected ± IL-1β for 20 days. First, we confirmed that IL-1-treated HSCs had unaffected clonogenic efficiency in methylcellulose and normal survival as measured by cleaved caspase-3 (CC3) levels compared with naive HSCs isolated from PBS-treated mice ( Supplementary Fig. 7a ). We then transplanted both naive and IL-1-treated HSCs into sublethally irradiated congenic recipients that were subsequently injected ± IL-1β for another 30 days to track lineage reconstitution and BM HSC chimaerism (Fig. 6a) . We observed accelerated donor blood output from naive HSCs exposed to IL-1 after transplantation (Fig. 6b) , which is consistent with earlier literature describing enhanced myeloid regeneration in similar conditions 21 . In contrast, donor blood output rapidly eroded in mice transplanted with IL-1-treated HSCs on continued IL-1 exposure (Fig. 6b and Supplementary Fig. 7b ). In both cases, IL-1 treatment following transplantation completely blocked donor lymphoid output and rebalanced blood production towards enhanced myelopoiesis (Fig. 6c and Supplementary Fig. 7b ). However, chimaerism analyses uncovered a near complete exhaustion of donor HSCs in the BM of mice transplanted with IL-1-treated HSCs, even in recipients not subsequently injected with IL-1 ( Fig. 6d and Supplementary Fig. 7c ). To determine whether these effects were due to IL-1-mediated PU.1 activation, we transplanted lentivirustransduced HSCs overexpressing PU.1 into sublethally irradiated recipient mice and tracked these mice for 30 days (Fig. 6e) . Strikingly, compared with control-transduced HSCs, we observed rapid erosion of donor blood output and complete exhaustion of PU.1-overexpressing HSCs in the BM (Fig. 6f,g and Supplementary Fig. 7d ), a behaviour similar to IL-1-exposed HSCs. Together, these shortterm lineage-tracking results indicate that although IL-1 treatment always enhances myeloid cell production regardless of its duration, it also severely compromises HSC function and blood regeneration in conditions of chronic exposure, probably through hyperactivation of PU.1.
To confirm the functional impairment of HSCs chronically exposed to IL-1, we transplanted naive and IL-1-treated HSCs into lethally irradiated recipient mice to assess long-term engraftment and selfrenewal activity after 4 months, and also performed limiting dilution analyses with unfractionated BM cells to address HSC function independently of surface markers ( Fig. 7a and Supplementary Fig. 8a) . In both cases, we observed significantly decreased donor chimaerism and reduced lymphoid output from IL-1-treated HSCs (Fig. 7b,c and Supplementary Fig. 8b,c) , reflecting compromised self-renewal activity. To investigate whether long-term IL-1 treatment could lead to HSC exhaustion, we also injected mice ± IL-1β for a total of 70 days (Fig. 7d) . Remarkably, even after such a long exposure, the HSC pool remained numerically intact though with an elevated frequency and number of myeloid-primed CD41
+ HSC LT43-45 and expansion of myeloid-biased MPP2/3 ( Supplementary Fig. 8d,e) . We also found that 70-day IL-1-treated HSC LT had unaffected survival in methylcellulose ( Supplementary Fig. 8f ), but significantly impaired self-renewal activity following transplantation (Fig. 7e,f) . These results demonstrate that chronic IL-1 exposure restricts HSC lineage output and severely compromises HSC regenerative function, thus priming IL-1-exposed HSCs to fail replicative challenges such as transplantation.
IL-1 effects are reversible on withdrawal
Last, we tested whether the damaging effects of chronic IL-1 exposure were retained by the HSC pool. We first re-transplanted into lethally irradiated recipient mice donor HSCs collected from mice initially reconstituted with naive and IL-1-exposed HSCs (20 days or 70 days; Fig. 7g and Supplementary Fig. 8g ). Remarkably we observed a complete recovery relative to naive controls in donor chimaerism and lineage output in HSCs derived from IL-1-treated donor mice, regardless of the length of the original IL-1 exposure (Fig. 7h,i and Supplementary Fig. 8h,i) . These results suggest that the remaining portion of the IL-1-exposed HSC pool was not functionally compromised. To assess whether IL-1 effects were reversible under native conditions, we used mice that were injected ± IL-1β for 20 days and allowed to rest without further treatment for 8 weeks (Fig. 8a) . After the rest period, blood parameters had fully normalized to untreated levels with a complete restoration of myeloid and B cell numbers (Fig. 8b) . Moreover, most of the BM changes had also reverted to untreated levels, with normal numbers of HSCs and MPPs, including MPP1, and restoration of the CLP compartment (Fig. 8c,d ).
The only persisting differences were increased GMP and decreased MPP4 numbers, which may reflect residual myeloid priming effects of the initial IL-1 treatment. Most importantly, donor chimaerism and lymphoid output were indistinguishable from untreated HSCs, indicating full restoration of self-renewal activity (Fig. 8e,f) . Taken together, these results demonstrate that the damaging effects of chronic IL-1 exposure on HSC regenerative functions are fully reversible on interruption of IL-1 exposure.
DISCUSSION
Our results demonstrate that IL-1 directly regulates HSC fate and instructs quick myeloid differentiation through precocious activation (g) Model for the effects of IL-1 on HSC function. At steady state, HSCs are essentially kept in a quiescent state that is geared towards maintenance of blood homeostasis. In this context, IL-1 is produced at low levels in the BM, primarily by granulocytes (Gr) and CD4 + T cells, and has minimal impact on HSC function. Following infection or injury, IL-1 is produced at elevated levels in the BM microenvironment, in particular by endothelial cells (EC) that form an essential component of the HSC niche, and thus can provide localized IL-1 signalling to HSCs. In this context, IL-1 functions as an 'emergency' signal that directly instructs HSCs towards myeloid differentiation, through activation of the NF-κB pathway and engagement of a PU.1-dependent myeloid gene program resulting in accelerated cell division and precocious differentiation into myeloid progenitors and ultimately mature myeloid cells. Although such a response is advantageous in the context of acute inflammation and blood regeneration, it is ultimately detrimental in situations of chronic exposure because IL-1-exposed HSCs lose their ability to differentiate into the lymphoid and erythroid lineages, and exhibit decreased self-renewal activity and regenerative potential in response to replicative challenges such as transplantation. However, these damaging consequences are fully reversible on IL-1 withdrawal, indicating that IL-1 effects are essentially transient and require continuous exposure to negatively impact HSC function. Source data for b-f are shown in Supplementary  Table 1 . Data are means ± s.d.; * P ≤ 0.05. All P values were determined by Mann-Whitney U-test. Exact P values, number of replicates used to derive statistical data (n) and statistical tests used are shown in Supplementary  Table 2 .
of an instructive PU.1 gene program and exclusive production of myeloid cells in 'emergency' situations such as myeloablation and transplantation (Fig. 8g ) 46 . These results imply that previous models, in which sustained low PU.1 levels initiate eventual myeloid commitment in progenitors 47 , do not apply in stress conditions. IL-1 has long been known to inhibit lymphopoiesis and erythropoiesis 38, 48, 49 although, paradoxically, high PU.1 levels also play a key role in B cell development 47 . It is therefore likely that rapid PU.1 induction in HSCs by IL-1 drives myelopoiesis while preventing the establishment of other gene programs specifying lymphopoiesis and erythropoiesis. Interestingly, PU.1 activation proceeds through IKK kinase, which is the primary activator of NF-κB, a known IL-1 target that is also downstream of TLRs 20 . As TLRs also induce HSC myeloid differentiation 50 , it is possible that PU.1 serves as a convergence point for these proinflammatory signals. Interestingly, the transcription factor C/EBPβ also regulates 'emergency' myeloid differentiation in response to IL-3 or GM-CSF in haematopoietic progenitors 51 , or to IFN-γ stimulation in HSCs 52 . It will therefore be interesting to investigate whether activation of PU.1 and activation of C/EBPβ represent distinct or converging mechanisms accelerating HSC myeloid differentiation in response to inflammation.
Our results also demonstrate that chronic IL-1 exposure significantly impairs HSC function. Notably, the numerical HSC pool is not depleted, consistent with previous results of long-term in vivo exposure to IFN-α 13 . This may reflect the recently described ability of the MPP compartment to 'buffer' myeloid demand independently of HSCs 53, 54 , or the replenishment of an IL-1-responsive HSC subset from quiescent HSC LT similar to the IFN-responsive CD41 + HSCs recently involved in emergency megakaryopoiesis 55 . This latest interpretation is supported by our observation that a fraction of, rather than all, HSCs activate PU.1 following IL-1 exposure, and the partial, rather than complete, functional impairment of IL-1-exposed HSCs. In this context, neither CD34 nor CD41 expression seems to separate IL-1-responsive from IL-1-non-responsive HSC LT , and further analyses will be required to identify ways to separate these two functional subsets. Interestingly, the deleterious effects of chronic IL-1 exposure on HSC function are largely resolved following IL-1 withdrawal, suggesting that they are not permanently 'imprinted' onto the HSC pool through epigenetic or other means. As IL-1 receptor blockers including anakinra are highly efficacious treatments for a wide range of chronic inflammatory diseases featuring deregulated blood production 19 , restoration of HSC function could be a key benefit of IL-1 blockade. Moreover, it is likely that IL-1 could play a similar dual role, both beneficial and pathogenic, in a variety of tissues by directly reprogramming their stem cell populations. Collectively, our findings demonstrate that IL-1 acts as a double-edged sword for HSC function, promoting myeloid regeneration without functional cost to HSCs during acute need, but significantly impairing their self-renewal and lineage output following chronic exposure. Modulation of IL-1 signalling, particularly its duration, may therefore be an important approach for broadly improving stem cell health and tissue function in the context of chronic inflammation or physiological ageing.
METHODS
Methods and any associated references are available in the online version of the paper. 
Mice. Congenic wild-type C57Bl/6 mice of both genders were bred in house and used for these studies. Il1r1 −/− mice 40 and PU.1-eYFP mice (gift from C. Nerlov, Oxford University, UK) were on a pure C57Bl/6 background, and PU.1∆URE mice 33 were on a mixed 129X1/SvJ × C57Bl/6 background. All experiments were performed in accordance with UCSF IACUC-approved protocols. Mice were analysed 21 days after transplantation and the zero-divisional cell fraction was determined according to the CFSE intensity of naive donor T cells as described previously 36 . Irradiated mice were maintained on antibiotic-containing water for at least 4 weeks following transplantation, and analysed for donor-derived chimaerism by regular bleeding. Peripheral blood (PB) was obtained from retro-orbital bleeding, and collected in 4 ml of ACK (150 mM NH 4 Cl/10 mM KHCO 3 ) containing 10 mM EDTA for flow cytometry analyses, or in EDTA-coated tubes (Becton Dickenson) for complete blood count analysis using a Hemavet 950 CBC analyser (Drew Scientific). HSC frequencies from limiting dilution assay experiments were calculated using ELDA software (http://bioinf.wehi.edu.au/software/elda) 56 . Engraftment was defined as ≥0.5% donor PB chimaerism at 16 weeks post-transplantation.
In vivo
Flow cytometry. BM stem and progenitor populations were analysed and/or isolated as described previously 30 . For cell sorting, BM cells were obtained by crushing leg, arm and pelvic bones from mice in Hanks' buffered saline solution (HBSS) containing 2% heat-inactivated FBS. Erythrocytes and contaminating bone cells were removed by ACK lysis followed by centrifugation on a Ficoll gradient (Histopaque 1119, Sigma-Aldrich). BM was subsequently enriched for c-Kit + cells using c-Kit microbeads (Miltenyi Biotec, 130-091-224) and an AutoMACS cell separator (Miltenyi Biotec). For population analyses, BM cells were flushed from one tibia and one femur per mouse and cellularity was determined using a ViCell automated cell counter (Beckman-Coulter). For wild-type mice, cells were incubated with purified, unconjugated lineage antibodies against CD3 (BioLegend, 100202), CD4 (eBioscience, 16-0041-82), CD5 (eBioscience, 14-0051-85), CD8 (eBioscience, 16-0081-82), B220 (eBioscience, 16-0451-82), Ter119 (eBioscience, 16-5921-85), Mac-1 (eBioscience, 16-0112-85) and Gr-1 (eBioscience, 14-5931-85), followed by goat anti-rat-PE-Cy5 (Invitrogen, A10691), subsequently blocked with purified rat IgG (Sigma-Aldrich) and stained with c-Kit APC-eFluor780 (eBioscience, 47-1171-82), Sca-1-PB (BioLegend, 108120), Flk2-Bio (eBioscience, 13-1351-82), CD48-A647 (BioLegend, 103416), CD150-PE (BioLegend, 115904), FcγR-PerCP-eFluor710 (eBioscience, 46-0161-82), CD34-FITC (eBioscience, 11-0341-85) and either SA-PE-Cy7 (eBioscience, 25-4317-82) or SA-Qdot605 (Invitrogen, Q10101MP). For identification of CD41 + HSCs, a staining including Lin/PE-Cy5, c-Kit-APC-eFluor780, Sca-1-PB, CD48-A647, CD150-PE-Cy7 (BioLegend, 115913), CD34-Bio (BioLegend, 119304) followed with SAQdot605, CD41-FITC (eBioscience, 11-0411-82) and CD229-PE (BioLegend, 122905) was performed. For identification of CLP, a separate staining including Lin/PE-Cy5, c-Kit-APC-eFluor780, Sca-1-PB, Flk2-Bio/SA-Qdot605 and IL7R-PE-Cy7 (eBioscience, 25-1271-82) was performed. For PU.1-eYFP mice, two separate stains were performed, one including CD150-PE, CD48-A647 and Flk2-Bio/SA-PE-Cy7, and the second one FcγR-PerCP-eFluor710 and CD34-Bio followed with SA-Qdot605 alongside Lin/PE-Cy5, c-Kit-APC-eFluor780 and Sca-1-PB. For sorting HSCs from IL-1-or 5-FU-treated mice, CD34 and FcγR were excluded and Mac-1 was stained separately from the lineage markers using Mac-1-PE-Cy7 (eBioscience, 25-0112-82) to control for potential increases in expression caused by IL-1, and HSC purity was further verified by inclusion of ESAM-FITC (Biolegend, 136205). Stromal BM ECs, MSCs and OBCs were isolated from haematopoietic-depleted, collagenase-treated bone chips as described previously 40 using Lin/PE-Cy5, Sca-1-PB, CD45-APC-Cy7 (BD Biosciences, 557659), CD31-FITC (BD Biosciences 558738) and CD51-Bio (BD Biosciences 551380) followed by SA-APC (eBioscience 17-4317-82 int/lo ) were identified and isolated as described previously 57 using Mac-1-PE-Cy7, Gr-1-PB (eBioscience, 57-5931-82), Ly6C-PE-Cy5.5 (Biolegend, 128012), M-CSFR-Bio (eBioscience 13-1152-81) followed by SA-Qdot605, and F4/80-APC (eBioscience, 17-4801-82). BM B cells (B220 + CD19 + ), CD4 + T cells (CD4 + ) and CD8 + T cells (CD8 + ) were identified and isolated using B220-APC-Cy7 (eBioscience, 47-0452-82), CD19-PE (eBioscience, 12-0193-82), CD3-APC (eBioscience, 17-0032-82), CD4-FITC (BD Biosciences, 553729), and CD8-PE (Biolegend, 100908). For assessing myeloid differentiation in cultures, the same c-Kit-APC-eFluor780, Sca-1-PB, FcγR-PerCP-eFluor710 and Mac-1-FITC (eBioscience 11-0112-82) were used, plus either M-CSFR-Bio/SA-Qdot 605 or CD18-Bio (BD Biosciences, 557439) followed by SA-PE-Cy7, in separate stains. For transplantation experiments, donor and recipient cells were distinguished using CD45.1-FITC (eBioscience, 11-0454-85) and CD45.2-PE (eBioscience, 12-0453) with Mac-1-PE-Cy7, Gr-1-PB, CD3-APC, and B220-APC-Cy7 to assess lineage reconstitution in PB and BM, and CD45.1-FITC and CD45.2-PE-Cy7 (eBioscience, 25-0453-82) with c-Kit-eFluor780, Sca-1-PB, Flk2-Bio/SA-Qdot605, CD48-APC and CD150-PE to assess lineage reconstitution in HSCs. Stained cells were resuspended in HBSS/2% FBS and 1 µg ml −1 propidium iodide (PI) to exclude dead cells. For CFSE dilution assays, cells were stained with biotinylated lineage antibodies and enriched for Lin − cells using anti-biotin microbeads (Miltenyi Biotec, 130-090-485) on MACS cell separation columns (Miltenyi Biotec), followed by SA-PB (Invitrogen, S11222), c-Kit-PE-Cy5 (BioLegend, 105810) and Sca-1-APC-Cy7 (BioLegend, 108126). T cells were enriched from spleen cells with a CD4-Bio (eBioscience, 13-0041-82) antibody and anti-biotin microbeads on MACS columns and subsequently stained with SA-PE-Cy5 (BioLegend, 405205) and CD62L-PE (eBioscience, 12-0621-81). Sorted LSK cells and CD4 + CD62L + naive T cells were subsequently labelled with 2 µM CFSE (Molecular Probes) as described previously 34 . For analysis of CFSE-labelled donor cells following transplantation, cells were stained with biotinylated lineage antibodies and enriched as above, followed by SA-Qdot605, CD45.1-eFluor 450 (eBioscience, 48-0453-82), CD45.2-PerCP-Cy5.5 (eBioscience, 45-0454-82), c-Kit-PE-Cy7 (eBioscience, 25-1171-81), Sca-1-APC-Cy7 (BioLegend, 108126), FcγR-BV510 (BioLegend, 101333), CD150-PE and CD34-A660 (eBioscience, 50-0341-80). Dead cells were excluded using Zombie Aqua Dye (BioLegend, 423102). For intracellular Ki67/DAPI staining, unfractionated BM cells were stained with Lin/PE-Cy5, c-Kit-APC-eFluor780, Sca-1-PE-Cy7 (BioLegend, 108113), CD150-PE and CD48-A647 and HSCs identified without Flk2. Isolated cells were washed in PBS, fixed with Cytofix/Cytoperm (BD Biosciences) for 30 min at 4 • C, washed in Permwash, permeabilized with Cytoperm Plus for 10 min at room temperature, washed again in Permwash, and stained with anti-Ki67-FITC (eBioscience, 11-5698-80) in Permwash for 2 h at 4 • C. Cells were washed with Permwash and resuspended in PBS/3% FBS containing 1 µg ml −1 DAPI and incubated for 20 min before analysis. Cell isolation was performed on a FACSAria II or III (Becton Dickenson) using double sorting, and cell analyses were performed using a FACS LSR II (Becton Dickenson). Additional antibody information, including clones and dilutions, is listed in Supplementary Table 3.
Cell culture. All cultures were performed at 37 • C in a 5% CO 2 water jacket incubator (Thermo Scientific). Cells were grown in StemPro34 medium (Invitrogen) supplemented with penicillin (50 U ml −1 )/streptomycin (50 µg ml −1 ) and L-glutamine (2 mM), SCF (25 ng ml −1 ), Flt3L (25 ng ml −1 ), IL-11 (25 ng ml −1 ), IL-3 (10 ng ml −1 ), GM-CSF (10 ng ml −1 ), Epo (4 U ml −1 ) and Tpo (25 ng ml −1 ) (Peprotech). IL-1α or IL-1β (Peprotech) was added at 25 ng ml −1 and M-CSF (Peprotech) at 100 ng ml −1 where indicated. For expansion assays, cells (400 per well) were directly sorted into 96-well plates and cultured for up to 8 days. For surface marker tracking experiments, cells (2,500-5,000 per well) were directly sorted into 96-well plates and cultured for up to 8 days. Cytokines were refreshed every other day by removing ∼30% of the total well volume and replacing with fresh media, and cultures were split as needed. For cleaved caspase-3 and ATP activity assays, cells (400 per well) were directly sorted into 384-well white luminescence culture plates containing 40 µl of media. Either directly after sorting or after 12 h an equal volume of Caspase-Glo 3/7 or CellTiter Glo substrate (Promega) was added to wells and the assay was performed according to the manufacturer's instructions. For pathway blockade assays, HSCs were cultured for 12 h ± 25 pg ml −1 IL-1β with either DMSO vehicle (1:1,000 dilution) or 10 µm PD-0325901 (MEK inhibitor; Shanghai Chemokine Co., CAS 391210-10-9), 10 µm rottlerin (PKC inhibitor; Tocris, 1610), 10 µm SB203580 (p38 inhibitor; Millipore, 559389), 10 µm BMS-345541 (IKK inhibitor; Sigma-Aldrich, B9935), 10 µm PP2 (Src inhibitor; Calbiochem, 529576), 
